GIST In the News

Deciphera has announced the topline results of the INTRIGUE trial examining the use of QINLOCK in the 2L setting. Please find a link to the press release here for your review. A paper written by ...

https://www.gistsupport.org/results-from-intrigue-trial-ripretinib/

The 2014 GIST Summit was held Saturday September 13, 2014 at MD Anderson Cancer Center in Houston, and it was the best ever! Watch videos now.

https://www.gistsupport.org/2014-gist-summit/

GIST Cancer Awareness Foundation and UCLA are hosting a free educational forum for GIST patients and caregivers on March 24 in Los Angeles.  See details below on how to register. For more about ...

https://www.gistsupport.org/ucla-gcaf-forum-march-24/

Boston University School of Medicine is conducting a study regarding GIST patients’ understanding of tumor testing and personalized medicine. Feel free to read more below! The direct link to th...

https://www.gistsupport.org/survey-on-mutation-analysis/

For more information about the NIH clinic for pediatric & wildtype GIST, see our webpages about past clinics.  Patients of all ages with wildtype GIST are encouraged to participate.  Participat...

https://www.gistsupport.org/2014-nih-wildtype-gist-clinic/

New combination trial for GIST:  imatinib plus MEK inhibitor MEK162 A new clinical trial opened in November 2013 at Memorial Sloan-Kettering Cancer Center to test the combination of imatinib (Gl...

https://www.gistsupport.org/combination-trial-imatinib-mek162/

Becky Bensanhaver and Nancy Berezin attended the ASCO meeting in June 2012 on behalf of GIST Support International and all GIST patients.  This is an effort reqiuring stamina, comfortable shoes,...

https://www.gistsupport.org/gist-news-from-2012-asco/

FDA Approves Stivarga (regorafenib) for GIST On February 25, 2013 the FDA approved regorafenib (brand name Stivarga) for treatment of GIST patients with “advanced gastrointestinal stromal tum...

https://www.gistsupport.org/regorafenib-approved/

On April 26, 2012  the FDA announced approval of pazopanib (votrient) for soft tissue sarcoma. Earlier the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted March ...

https://www.gistsupport.org/votrient-approved-for-sarcoma/

FDA news release, Jan 31, 2012: FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer Confirmatory trials show significantly prolonged survival in patients; drug gra...

https://www.gistsupport.org/fda-approves-adjuvant-gleevec-extension-to-3-years/